ArticleFrontiers in endocrinology2026
Cardiovascular risk factors in autoimmune thyroiditis: role of adiponectin, resistin, inflammation and auto-immunity - a cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Autoimmune thyroiditis (AIT) has been associated with an increased cardiovascular risk. Whether adipokines, inflammation and auto-immunity contribute to this increased risk is uncertain. Our aim was to evaluate the interrelationships of adipokines, inflammation, auto-immunity, and thyroid function with cardiovascular risk in autoimmune thyroiditis. Methods: Sixty-two patients with AIT, with normal free T4 (FT4) and free T3 (FT3), without other comorbidities were studied. Patients were divided into two groups: AIT with thyroid-stimulating hormone (TSH) ≤2.5 mU/L and AIT with TSH >2.5 mU/L. Parameters of thyroid function tests, serum lipid, high sensitivity C-reactive protein (hs-CRP) and homocysteine levels, anti-thyroglobulin antibodies, anti-thyroid peroxidase (TPO) antibodies, adiponectin and resistin were measured. Results: Patients with TSH >2.5 mU/L had significantly higher body mass index, higher low density lipoprotein (LDL)-cholesterol levels, and lower lipoprotein(a) levels. No differences in triglycerides, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), adiponectin, or resistin levels were observed between groups. In the overall cohort, adiponectin levels were positively correlated with high density lipoprotein (HDL)-cholesterol and lipoprotein(a), whereas resistin was positively correlated with hs-CRP and triglyceride levels. Hs-CRP levels were positively correlated with anti-thyroglobulin antibody titers, and homocysteine levels were negatively correlated with FT3. In the subgroup with TSH >2.5 mU/L, FT4 was positively correlated with ApoA1 and HDL-cholesterol and negatively correlated with lipoprotein(a), while resistin was positively correlated with TSH. In patients with TSH ≤2.5 mU/L, adiponectin levels were negatively correlated with TSH. Conclusion: Our study highlights a complex interrelationship between cardiovascular risk factors in patients with AIT. Patients with AIT and TSH >2.5 mU/L may have a more atherogenic lipid profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.